Cancer firm Adcendo raises EUR 51m
Danish biotech firm Adcendu secures EUR 51m from various investors including Novo Seeds. This is the largest A series investment round in the history of Danish biotech.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Less than one year after Adcendo selected its primary drug candidate, the Danish biotech firm has raised more than EUR 51m (USD 61.8m) in a series A financing round.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings beats records in 2020 and earns DKK 29bn
For subscribers
